Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the GLP-1 and GIP receptors. VKTX is ...
MIAMI, FL, June 24, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
A New Drug Application for the EE and NERD indications for tegoprazan will be submitted in the fourth quarter of 2025. Topline data were announced from the maintenance phase of a phase 3 trial ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
Abivax (ABVX) stays a Buy as obefazimod UC data fuels multi‑billion potential; 2026 Phase 3/NDA catalysts loom and M&A ...
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results